Danaher Joins Bespoke Gene Therapy Consortium (BGTC) for Rare Diseases
Consortium aims to speed the development and delivery of customized or 'bespoke' gene therapies
WASHINGTON, May 12, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it has joined the Bespoke Gene Therapy Consortium (BGTC). Launched in October 2021, the BGTC will generate gene therapy resources that the research community can use to streamline gene therapy development for rare disorders, making the process more efficient and less costly. Danaher's Life Science companies join the Food and Drug Administration (FDA), the National Institutes of Health (NIH), twelve pharmaceutical and biotech companies and nine non-profits, and will be represented by experts from Danaher Corporation and its companies, notably Pall Corporation, Aldevron and Cytiva. The project is managed by the Foundation for the National Institutes of Health (FNIH) as part of the Accelerating Medicines Partnership® program.
"Danaher's companies have a history of working with drug developers to provide new technologies and services that enable the advancement of breakthrough genomic medicines," said Sadik Kassim, Chief Technology Officer, Genomic Medicines for the Life Sciences companies at Danaher. "We are committed to continuing our work in this space and to collaborating with the NIH, FDA, and like-minded industry partners to accelerate the development of platform technologies and diagnostics that enable the next generation of breakthrough therapies."
The BGTC was formed in response to shortcomings in the current drug development model that make it difficult for companies to recover the costs required to develop gene therapies to treat rare and ultra-rare diseases.
"The Life Sciences companies of Danaher have the global presence and broad capabilities to support Genomic Medicine researchers and the industrial scale-up of biological treatments, making them ideal contributors to the BGTC. We are confident that their reach and expertise will help the BGTC realize its goal of streamlining he drug development process to reduce costs and enable companies to bring more gene therapies to patients," said Courtney Silverthorn, Associate Vice President of Research Partnerships at the FNIH.
"The COVID-19 pandemic has shown the world what is possible when partners from the public, private and non-profit sectors come together to solve big, societal challenges," said Jose-Carlos Gutierrez-Ramos, Chief Science Officer at Danaher. "We believe collaborations like the BGTC are critical to unlock bottlenecks in the development of therapies for rare and ultra-rare diseases."
Learn more about BGTC by visiting https://fnih.org/our-programs/AMP/BGTC.
ABOUT THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH
SOURCE Danaher Corporation
Session Details TBA
Smart Protection â€“ How IoT Helps Protect and Serve
We Only have 5 Senses, but Things have Sensors Galore